Raptor Pharmaceutical Corp. said Monday its developing treatment for the genetic disorder nephropathic cystinosis met key goals in a midstage study.
The company said the drug candidate DR Cysteamine met tolerability and dosing goals.
Raptor said it plans to meet with the Food and Drug Administration and European Medicines Agency to discuss the results of its study. The company hopes to start late-stage developing in the first quarter.
Nephropathic cystinosis involves the accumulation of amino acid in cells, which can damage bodily systems, including the kidneys.
Shares of Raptor rose 28 cents, or 8 percent, to $3.78 in morning trading. The stock has traded between 7 cents and $4.90 over the last 52 weeks.